With 0.58 million shares changed hands, the volume of the stock remained lighter than its average volume of 7.59 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.479 whereas the lowest price it dropped to was $0.4007. The 52-week range on IPA shows that it touched its highest point at $1.39 and its lowest point at $0.27 during that stretch. It currently has a 1-year price target of $4.01. Beta for the stock currently stands at 0.27.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IPA was up-trending over the past week, with a rise of 6.75%, but this was down by -4.20% over a month. Three-month performance dropped to -10.65% while six-month performance fell -30.10%. The stock lost -69.78% in the past year, while it has lost -0.17% so far this year. A look at the trailing 12-month EPS for IPA yields -1.13 with Next year EPS estimates of -0.08. For the next quarter, that number is -0.03. This implies an EPS growth rate of 42.59% for this year and 82.54% for next year.
Float and Shares Shorts:
At present, 45.77 million IPA shares are outstanding with a float of 21.62 million shares on hand for trading. On 2025-03-31, short shares totaled 1.59 million, which was 347.99999999999994 higher than short shares on 1740700800. In addition to Dr. Jennifer Lynne Bath Ph.D. as the firm’s CEO, President & Non-Independent Director, Dr. Ilse Roodink serves as its Chief Scientific Officer & Interim General Manager of IPA Europe, Oss.
Institutional Ownership:
Through their ownership of 0.04167 of IPA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-01-31, IPA reported revenue of $6151000.0 and operating income of -$3293000.0. The EBITDA in the recently reported quarter was -$1897000.0 and diluted EPS was -$0.66.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With IPA analysts setting a high price target of 5.0 and a low target of 3.0, the average target price over the next 12 months is 4.0. Based on these targets, IPA could surge 1119.51% to reach the target high and rise by 631.71% to reach the target low. Reaching the average price target will result in a growth of 875.61% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.46542 being high and -$0.47684 being low. For IPA, this leads to a yearly average estimate of -$0.47113. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
